Precision in pharma: The critical role of due diligence for industry success
Published on February 21, 2024
Due diligence in pharma is emerging as a critical tool for success. Our experts explain why accuracy in due diligence matters, now more than ever, and how it’s shaping the future of the pharmaceutical industry.
The early weeks of 2024 are a clear sign of accelerated dealmaking, potentially setting the course for growth in the year ahead.
The J.P. Morgan Healthcare Conference in San Francisco showcased important developments:
- Dealmaking is making a comeback: Headwinds for the pharmaceutical industry, such as empty pipelines and a looming patent cliff, result in a heightened need for portfolio diversification. Experts predict that late-stage and therefore lower risk assets will make up large parts of dealmaking in 2024.
- Antibody Drug Conjugates (ADCs) are center-stage: At the end of 2023 and in the early weeks of the new year, many players were strengthening their drug pipeline with the new “star…
